



Early Detection of Kidney Cancer: Biochemical Assay Using New And Sensitive Tumor Marker

Rasha Hasan Jasim^{1*}, Hathama Razooki Hasan² and Majed Khadum Husain³

1. Chemistry Department, College of Education for Girls, University of Kufa, **IRAQ**
2. Chemistry Department, College of Science, University of Baghdad, **IRAQ**
3. Biochemistry Department, College of Medicine, University of Kufa, **IRAQ**

Email: dr.rashahussainee@yahoo.com

Accepted on 11th December 2014

ABSTRACT

The first mammalian lectin was isolated by Gilbert Ashwell and Anatol Morell, meanwhile, first member of the β -galactose-specific lectins family was isolated from the electric eel. The number of purified animal lectins has started to grow quickly since the beginning of the 1980. Recently, studies directed to human were carried out concerning detection, purification, identification, determination of physical and chemical properties, as well as determination of lectins levels in the normal and abnormal individuals. The present study was designed to investigate lectins in sera of patients with kidney tumors, in addition to non tumoral kidney disease patients. Fifty five patients of malignant kidney tumors were enrolled in addition to 23 patients of benign kidney tumors, and 18 patients of non tumoral kidney diseases used as control groups, in addition to 46 healthy individuals were also investigated. The measurement of total serum proteins revealed significant ($p < 0.001$) decrease in patients of malignant tumors when compared with those of benign, non tumoral diseases, and healthy individuals. The conditions of the hemagglutination assay of serum lectin activity were optimized. The cutoff value of the specific hemagglutination activity was found to equal 6 SHU for discriminatory malignant kidney tumors. Serum lectins activity were indicated to be inhibited by galactose, mannose, lactose and N-acetyl galactosamine. Purification of lectin from sera of patients with malignant kidney tumors by affinity chromatography with the use of silver stain revealed LacBL PAGE of purified lectin demonstrated one band consisted lectin activity. These results suggest that the diagnosis of the specific hemagglutination activity of lectin is promising biomarker for discrimination of malignant kidney tumor patients and the purified lectin could be introduced in the field of biomarkers.

Keywords: Lactose Binding Lectin, kidney tumors, cancer, purification.

INTRODUCTION

Lectins are ubiquitous proteins or glycoproteins that are present in all eukaryotic cells [1-6], and many bacterial species [7, 8], as well as in some viruses [9, 10]. They are capable to bind mono- and oligosaccharides with high affinity [11, 12], and usually agglutinate cells or precipitate polysaccharides and glycoconjugates specifically and reversibly [13, 11]. The binding involves hydrophobic interactions as well as hydrogen bonds [14]. Lectin specificity for individual sugars or groups of sugars makes them

powerful tools for detecting changes in the carbohydrate structure of the glycoproteins [15, 16]. Several lectins are investigated for their use in cancer research and therapy. Preliminary findings suggest that some lectins can detect alterations of malignant cells as well as reduce the cancer cell tumorigenicity and thus may be helpful for prognosis of the immune status of the patients [17].

During malignancy, an increased expression of oncogene proteins due to chromosomal translocation, amplification, deletion or mutation that is considered one of the main alterations in the cancer cells, Lectin may be one of these proteins. Genetic imprinting errors and genetic instability leading to progressive loss of regulated cell proliferation, increased invasiveness, and increased metastatic potential. Expression of lectins is completely controlled by the machinery system of protein synthesis. Therefore, it is prone for alteration during malignant transformation [4].

Present study designed to investigate the kidney cancer effect in activation of glycosylation reaction through purification and evaluate lactose binding lectin as a product to stimulation of enzymes of this pathway.

MATERIALS AND METHODS

Patient and Control Individuals: The present study involved 96 patients (55 cases with malignant kidney tumors, 23 cases with benign kidney tumors, and 18 cases with non tumoral kidney diseases) with the age range 10-80 years, in addition to 46 healthy individuals, at the same age range.

Isolation of Crude Lectins from Serum Specimens: Ten milliliters of venous blood samples were collected from patients and the control groups. Samples were allowed to clot at room temperature, centrifuged at 3000 xg for 5 min, and then sera were collected and stored at -15°C . For isolation of serum crude lectins, 1 volume of serum was mixed with 2.5 volumes of petroleum ether for defatting. The mixtures were shaken strongly, then, centrifuged at 3000 xg for 5 min. The organic phase was neglected and defatted serum was stored at -15°C to be used for determination of the hemagglutination activity.

Preparation of Standard Trypsinized Erythrocyte Suspension for Hemagglutination Test: Human blood group O^+ erythrocytes were collected from the local blood bank in Al-Sadder Teaching Hospital in Najaf in Iraq. Blood was centrifuged at 3000 xg for 5 min, the sera were discarded. The erythrocytes were washed with saline solution (5 mL saline: 1 mL packed erythrocytes), then were suspended in phosphate buffer saline solution (pH 7.4), and diluted with the same buffer to give an absorbance of 2 ml at 620 nm. One part of trypsin solution (1%) was added to 10 parts of the final erythrocytes suspension. The mixture was incubated at 37°C for 1 h, and then centrifuged at 5000 xg for 5 min. The trypsinized erythrocytes mixture was washed 3-5 times with saline solution to remove trypsin traces. Saline solution was added, until the absorbance of the erythrocyte suspension was 1.4 at 620 nm.

Protein Determination: Total proteins in the studied samples were estimated using Bradford method [18] and bovine serum albumin was used as a standard protein.

Determination of Hemagglutination Activity of Crude Serum Lectins of Patient and Control Groups: To determine the hemagglutination activity in serum Lis and Sharon [19] method was used, with essential modifications. The procedure involved three tubes, test (T), blank (B), and control (C). A set of control tubes (2 – 4) were used in each experiment and the assay was carried out as in the following:

Components	Test	Blank	Control
1) Diluted serum (1:20) with Tris-HCl buffer (20 Mm, pH 8)	1 mL	1 mL	-
2) Trypsinized erythrocyte suspension.			
3) Saline solution.	2 mL	-	2 mL
4) Calcium chloride solution (60 mM).	-	2 mL	1mL
	1 mL	1 mL	1 mL

T, B, and C tubes were placed in exactly vertical position at 37°C for 75 min.
Cells were separated after centrifugation at 3000 xg for 3 min, then re-suspended in the above mentioned buffer by gentle shaking, and allowed to stand for another 75 min at 37°C.

The absorbance of 2 mL of the upper mixtures was measured at 620 nm.

The reduction of optical density (ROD) in the test tube (in crude sera determination) was measured from the following equation:

$$ROD\% = \frac{A_C - A_{T-B}}{A_C} \times 100$$

Where:

A_C : Optical density of cell suspension in the control tube.

A_{T-B} : Optical density of cell suspension in the test tube – Optical density of cell suspension in the blank tube.

Purification of LacBL: Affinity chromatography technique was applied for the purification of LacBL from patients with malignant kidney tumors. Preparation of the affinity chromatography column was carried out according to the instructions of Hermanson [20], and Amersham handbook [Amersham Pharmacia Biotech].

Determination of Carbohydrate Content in the Purified LacBL: Dubois method [21] was followed for determination of carbohydrate amount in the purified LacBL. Where glucose was used as a standard sugar.

RESULTS AND DISCUSSION

Levels of The Serum Specific Hemagglutination Activity In Patients and Control Groups: The optimized conditions of the hemagglutination protocol were used for estimation of individual serum lectin activity in the studied groups. It was expressed as specific hemagglutination activity unit (SHU). **Figure 1** demonstrates that 52 patients out of the 55 studied patients of malignant kidney tumors have a hemagglutination activity higher than 6 SHU, while those of non tumoral kidney diseases and healthy individuals (except one sample in each group) have less than 6 SHU. Also those of benign kidney tumors were found to have specific activity less than 6 SHU. These results suggest the possibility of using 6 SHU as a cutoff value for the specific hemagglutination activity. A result showed the possibility of using this parameter as a biomarker for discriminating of patients with malignant kidney tumors among those with benign, non tumoral kidney diseases, and healthy individuals.




Figure 1: Distribution of the Serum Hemagglutination Activity in Patients of Malignant Kidney Tumors (K_1), Benign Kidney Tumors (K_2), Non Tumoral Kidney Diseases (K_3), and Healthy Individuals (H). The symbol - - - refer to the cutoff of malignant kidney tumors value

The evaluation of the specific hemagglutination activity in the various groups revealed a significant increase ($p < 0.001$) in patients of malignant kidney tumors when compared with those of benign tumors, non tumoral kidney diseases, and healthy individuals. However, non significant variations were obtained when other groups were compared together (**Table 1**). The sensitivity and specificity of serum lectin activity in detection of malignant kidney tumors were 94.54 % and 95.65 % respectively.

Table 1: Serum Specific Hemagglutination Activity Levels in Patients of Malignant Kidney (K_1) and Benign Kidney (K_2) Tumors, Non Tumoral Kidney Diseases (K_3), and Healthy Individuals (H_{K1} and H_{K2})

Groups	Age (year) Mean \pm S.D. Range	SHU Mean \pm S.D.	Range	<i>p</i>
K_1 (55)	54.93 \pm 12.50 32 – 80	14.99 \pm 6.21	4.79 – 29.08	0.000** for K_1 vs K_2 0.000** for K_1 vs K_3
K_2 (23)	45.04 \pm 15.33 10 – 66	3.04 \pm 1.31	1.17 – 6.49	0.309 for K_2 vs K_3
K_3 (18)	42.39 \pm 16.60 12 – 68	4.44 \pm 4.27	0.99 – 20.70	0.000** for K_1 vs H_{K1}
H_{K1} (32)	47.38 \pm 10.92 32 – 80	4.27 \pm 1.87	1.09 – 9.09	0.491 for K_2 vs H_{K2}
H_{K2} (43)	39.77 \pm 13.77 10 – 66	3.94 \pm 1.71	1.09 – 9.09	0.724 for K_3 vs H_{K2}

In the present study, the hemagglutination activity levels in 21 patients with malignant kidney tumors were followed up for 72 h after surgical operation, of the removal of the tumor. the result showed presence of a decrease in their serum hemagglutination activities after the removal of the tumors (data not shown).

Implication of Stages of Malignancy in Serum and Tissue Specific Hemagglutination Activity: In order to verify the changes of the hemagglutination activity with the advancing of malignancy, the patients were subdivided according to the stage of the diseases into stage I, II, III, and IV. From the statistical analysis of the malignant kidney tumors of different stages, a positive correlation was observed between the serum specific hemagglutination activity & the malignant tumor progression ($r = 0.767$ at $p < 0.0005$) (**Figure 2**).




Figure 2: Correlation of Serum Hemagglutination Activity with Stages of Malignant Kidney Tumors

Table 2: The Differences in Serum Specific Hemagglutination Activity of Malignant Kidney Tumor Patients According to the Stage of the Disease.

Subjects	Age (year) Mean± S.D. Range	SHU Mean± S.D.	Range	p
Stage I (14)	49.07 ± 11.94 32 – 74	8.03 ± 2.40	4.79 – 12.80	0.000** For (1, 2, 3, 4, and 5) 0.011 for (6)
Stage II (12)	55.67 ± 13.85 34 – 79	12.40 ± 1.21	10.37 – 14.42	
Stage III (11)	53.73 ± 9.71 43 – 75	17.58 ± 2.73	13.87 – 23.47	
Stage IV (18)	59.72 ± 12.40 41 – 80	20.55 ± 5.57	7.97 – 29.08	

- 1) Stage I vs. Stage II
- 2) Stage I vs. Stage III
- 3) Stage I vs. Stage IV
- 4) Stage II vs. Stage III
- 5) Stage II vs. Stage IV
- 6) Stage III vs. Stage IV

Gender Involvement in Kidney Lectins Hemagglutination Activity Changes: The effect of gender on the kidney specific hemagglutination activity levels in patients of cancerous tumors, benign tumors, and non tumoral kidney subgroups was evaluated. **Student's t-test** failed to exhibit significant changes among male and female patients (Table 3).

Table 3: Gender Differences of Serum Specific Hemagglutination Activity in Tumoral and non Tumoral Kidney Disease Patients and Healthy Individuals.

Type	Gender	Age (year) Mean ± S.D. Range	SHU Mean ± S.D.	Range	p
K ₁ (55)	M (36)	57.31 ± 13.69 32 – 80	15.48 ± 6.94	4.79 – 29.08	0.259
	F (19)	50.79 ± 9.19 37 – 65	14.08 ± 4.55	7.97 – 21.69	
K ₂ (23)	M (14)	43.93 ± 16.73 10 – 66	2.40 ± 0.77	1.17 – 3.59	0.377
	F (9)	47.44 ± 12.28 25 – 62	4.04 ± 1.38	2.45 – 6.49	
	M	47.36 ± 11.33	3.95 ± 1.23	2.05 – 6.00	

K_3 (18)	11)(F	27 – 62 34.57 ± 21.22	5.21 ± 6.92	0.99– 20.70	0.550
	(7) M	12 – 68 44.24 ± 9.57	4.69 ± 2.08	1.09– 9.09	
H (46)	(21) F	10 -81 44.88 ± 17.10	3.53 ± 1.14	1.09 – 6.13	0.432
	(25) M	11– 87			

K_1 : Malignant Kidney Tumor Patient group, K_2 : Benign Kidney Tumor Patient group, K_3 : Non Tumoral Kidney Patients, and H: total healthy individuals. M: Male, F: Female. The mean difference is significant at 0.001 level

Previously, the source of increased serum lectins in cancer patient was reported to be unclear but these increases may explain through the malignant tumors are the sources of lectin present in the sera of the malignant patients.

Increased levels of lectins in malignant tumor specimens may be due to: during malignancy, an increased expression of oncogene proteins due to chromosomal translocation, amplification, or mutation that is considered one of the main alterations in the cancer cells. Lectin may be one of these proteins. In malignant tumor cells, the loss of tumor suppressor gene protein products due to deletion or mutation, may lead to increase the oncogene proteins, where lectin may be among them. Genetic imprinting errors and genetic instability leading to progressive loss of regulated cell proliferation, increased invasiveness, and increased metastatic potential. Expression of lectins is completely controlled by the machinery system of protein synthesis. Therefore, it is prone for alteration during malignant transformation [4]. The elevation in several carbohydrates concentrations in malignant cells and the aberrant glycosylation of glycoproteins [16] can be considered one of the causes for lectin production.

In the present study, removal of the tumors, decreased serum hemagglutination activity, thus tumor tissues are most likely to produce and secrete lectins in sera. The agglutination test of cancerous tissues showed that lectin was found not only on malignant cells but also in macrophages and stromal cells (mainly fibroblasts) near cancer focus, and the stromal cells immediately adjacent to cancer nests was found to have higher levels of the hemagglutination activity in comparison to cells far from the nests. These results suggest that circulating lectins are generated not only by tumor cells but also from peritumoral inflammatory cells and stromal cells.

Purification of Serum Human LacBL: Hydrophobic affinity chromatography was used for isolation and purification of LacBL from sera of patients with malignant kidney tumors. The purification protocol was carried out by using sepharose 6B column activated with bis-oxirane (1, 4 – Butanediol diglycidyl ether) ($C_{10}H_{18}O_4$). The chromatogram of the purified GalNAcBL was demonstrated in **figure 3**.




Figure 3: Affinity Chromatogram of Malignant Lactose Binding Lectin (LacBL) using Sepharose 6B // Lactose Column (1.6×1.3) at Flow Rate 30ml / hour. The volume of each fraction was 1 ml. Tris Buffer 20mM and 7.4 pH was used as a Washing Solution. Elution step was carried out with Tris Buffer (20 mM, pH 7.4) contained 30 mM Lactose.

The purification folds and the yield of LacBL from malignant kidney tumors were 130 with 16.9.

Table 4: Results of the Purification Protocol of Lectins from Sera of Patients with Malignant Kidney Tumors

Purification step	Total volume (ml)	Total protein (mg)	Total activity (HU)	SHU (HA/ μ g of protein)	Purification (fold)	Yield %
<i>MKT Serum</i>	3	45	44.325	0.985	1	100
<i>LacBL</i>	7	0.0585	7.486	127.966	130	16.9

MKT: Malignant Kidney Tumor Serum; LacBL: Lactose Binding Lectin

The analysis of PAGE electrophoresis pattern of purified lectins from patients with malignant kidney tumors is shown in **figure 4**.




Figure 4: Conventional Polyacrylamide Gel Electrophoresis (PAGE) 7.5% for Proteins. Tris - glycine buffer (0.075 M, pH 8.9) used as the electrode buffer. Electrophoresis conditions were 50 mA as a constant current for 30 minutes, with voltage of 15 v/cm, and at 4°C. Electrophoresis was carried out for 10 minutes at 20mA, then the process was continued for 3.5 hours at 4°C by using 40 mA as a constant current and voltage of 15 v/cm. The gel was stained for protein with silver stain.

The approximate molecular weights of purified LacBL was determined using conventional PAGE. Five standard proteins with known molecular weights (Lysozyme 13.6 kD, Chymotrypsinogen 25 kD, Ovalbumin 47 kD, Bovine Serum Albumin 67 kD, Lactate Dehydrogenase 140 kD) were used. The estimated molecular weight of LacBL was 57.94.

LacBL Activity toward Various Human Blood Groups: To examine the sensitivity of purified LacBL in the agglutination reactions, blood of A⁺, B⁺, and O⁺ groups were used as the source of the erythrocyte samples. A⁺ RBCs were indicated to exhibit the maximal agglutination, among the evaluated blood groups. This finding could be explained by differences in glycosylation of the surface proteins of red blood cells [23]. Several studies tested the effect of blood sources on the hemagglutination process of purified lectins from various sources [24-26]; the result of the present study agreed with some and disagreed with the others.

Inhibition of LacBL Activity by EDTA: The hemagglutination process was carried out for the purified LacBL using human A⁺ red blood cells trypsinized suspension in the presence of EDTA. LacBL failed to lose its hemagglutination activity in the presence of EDTA, even at concentration of 9 mM. This result

clearly indicate that Ca^{2+} is not crucial for the expression of the hemagglutination activity of LacBL, thus; LacBL should be classified as calcium independent lectin.

Relevance of LacBL Activity with pH Changes: The effect of pH on the activity of the purified LacBL was investigated. Figure 5 points out that maximal lectin activity was achieved at pH 7.4, while the purified lectins were sensitive to acidic (pH 3) and to basic (pH 12) conditions, under which the activities were completely lost.




Figure 5: Effect of the pH on Purified LacBL Hemagglutination Activity

Thermal Stability of LacBL Activity: To explore the effect of temperature on the hemagglutination activity of purified LacBL, it was incubated at various temperatures (0°C , 30°C , 40°C , 50°C , 60°C , 80°C , and 100°C) for 1 hour; the mixtures were cooled until room temperature. The hemagglutination activity was carried out at 30°C [26]. Thermal stability results revealed that purified lectins remained stable below 40°C for one hour with no loss of hemagglutination activity, while; they loss about 40% of their hemagglutination activity at 50°C . Lectin activity disappeared when the denaturation was carried out at more than 60°C (Figure 6).




Figure 6: Thermal Denaturation of Purified LacBL Hemagglutination Activity

The influence of temperature on the hemagglutination activity of purified LacBL was also evaluated through the incubation of purified LacBL with erythrocyte suspension at 0 , 32 , 37 , 45 , 60 , and 75°C . Purified LacBL illustrated the highest hemagglutination activity at 30°C (Figure 7).




Figure 7: Temperature Effect on the Purified LacBL Hemagglutination Activity

The Carbohydrate Content in Purified Lectins: Total carbohydrate content was found to be 16.5 % from the purified LacBL.

APPLICATIONS

These results suggest that the diagnosis of the specific hemagglutination activity of lectin is promising biomarker for discrimination of malignant kidney tumor patients and the purified lectin could be introduced in the field of biomarkers.

REFERENCES

- [1] A.M.Vranken, E.J.Van Damme, A.K.Allen, W.J.Peumans, Purification and properties of an N-acetylgalactosamine specific lectin from the plant pathogenic fungus *Rhizoctonia solani*, *Federation of European Biochemical Societies J*, **1987**, 216(1), 67-72.
- [2] E.M.Rapoport, L.S.Zhigis, E.Y.Korchagina, T.V.Ovachinnikova, V.P. Zubov, N.V.Bovin, Isolation and characterization of galactose-binding lectins from human serum, *Russian Bioorganic Chemistry J*, **1996**, 22(55), 353-357.
- [3] M.Kakiuchi, N.Okino, N.Sueyoshi, S.Ichinose, A.Omori, S.Kawabata, K.Yamaguchi, M. Ito, Purification, characterization and cDNA cloning of α -N- acetylgalactosamine-specific lectin from starfish, *Aserina pectifera*, *Glycobiology J*, **2012**, 12(2), 85-94.
- [4] R.W. Raymond, Biochemistry of Cancer. In: *Cancer Biology*, **2007**, Section 1.p 108-120.
- [5] J.Pela'ez, J.A. Long, Characterizing the glycocalyx of poultry spermatozoa: I. Identification and distribution of carbohydrate residues using flow cytometry and epifluorescence microscopy, *Andrology J*. **2007**, 28(2), 342-352.
- [6] J.Y.Kim, Y.M.Kim, S.K.Cho, K.S.Choi, M.Cho, Noble tandem -repeat galectin of Manila clam *Ruditapes philippinarum* is induced upon infection with the protozoan parasite *Perkinsus olseni*, *Developmental and Comparative Immunology J*, **2011**, 32, 1131-1141.
- [7] N.Rudenko, M.Golovechenko, L.Grubhoffer, Lectin-like sequences in genome of *Borrelia burgdorferi*, *Folia Parastologica J*, **1999**, 46, 81-90.
- [8] M.Zampini, L.Canesi, M.Betti, C.Ciacci, R.Tarsi, G.Gallo, C.Pruzzo, Role for Mannose-Sensitive Hemagglutinin in Promoting Interactions between *Vibrio cholerae* El Tor and Mussel Hemolymph, *Applied and Environmental Microbiology*, **2009**, 69(9), 5711-5715.
- [9] L.Opitz, J.Salakang, H. Büttner, U. Reichl, M.W.Wolff, Lectin-affinity chromatography for downstream processing of MDCK cell culture derived human influenza A viruses, *Vaccine*, **2007**, 25, 939-947.
- [10] A.Chandrasekaran, A.Srinivasan, R.Raman, K.Viswanathan, S.Raguram, T.M.Tumpey, V.Sasisekharan, R.Sasisekharan, Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin, *Nature Biotechnology J*, **2008**, 10, 1-7.

- [11] F.A.De Wolf, G.M.Brett, Ligand-Binding Proteins: Their Potential for Application in Systems for Controlled Delivery and Uptake of Ligands, *Pharmacological Reviews*, **2010**, 52(2), 207-236.
- [12] C.Pierini, Lectins: Their Damaging Role in Intestinal Health, Rheumatoid Arthritis and Weight Loss, *Vitamin Research News J*, **2007**, 21(1), 1-4.
- [13] I.J.Goldstein, R.C.Hughes, M.Monsigny, T.Ozawa, N. Sharon, What should be called a lectin? *Nature J*, **1980**, 285, 60-65.
- [14] R.Brossmer, M.Wagner, E. Fischer, Specificity of the sialic acid-binding lectin from the snail *Cepaea hortensis*. *Biol Chem. J*, **1992**, 267, 8752-8756.
- [15] S.R.Olivera, A.E.Nascimento, M.E.Lima, Y.F.Leite, N.M.Benevides, Purification and characterization of a lectin from the red marine alga *Pterocladia capillacea* (S.G. Gmel.) Santel. & Hommers, *Revista Brasil. Bot. J*, **2009**, 25(4), 397-403.
- [16] P.A.Mayes, D.A.Bender, Overview of Metabolism. In: Murray R K, Granner D K, Mayes P A, & Rodwell V W: Harper's Illustrated Biochemistry. Lange Medical Publications. 27th Edition. **2011**
- [17] S.R.Pine, L.E.Mechanic, S.Ambs, E.D.Bowman, S.J.Chanock, C.Loffredo, P.G.Shields, C.C.Harris, Lung Cancer Survival and Functional Polymorphisms in MBL2, an Innate-Immunity Gene, *J. Natl Cancer Inst*, **2009**, 99, 1401-1409.
- [18] M.Bradford, A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. *Anal. Biochem. J*. **1976**, 72, 248-254.
- [19] H.Lis, N.Sharon, Lectins as molecules and as tools, *Ann. Rev. Biochem*, **1987**, 55, 35-67.
- [20] G.T.Hermanson, A.K.Mallia, P.K.Smith, Immobilized Affinity Ligand Techniques. UK. Academic Press, Inc. **1992**.
- [21] M.Dubois, K.A.Gilles, J.K.Hamilton, P.A.Robers, F.Smith, Colorimetric method for determination of sugars, and related substances, *Annal. Biochem*, **1956**, 28, (3), 350-356.
- [22] I.Iurisci, N.Tinari, C.Natoli, D.Angelucci, E.Cianchetti, S.Iacobelli, Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients. *Clinical Cancer Research*, **2000**, 6, 1389-1393.
- [23] R.S.Percival, P.D.Marsh, D.A.Devine, M.Rangarajan, J.Aduse, P.Shepherd, M.A.Curtis, Effect of Temperature on Growth, Hemagglutination, and Protease Activity of *Porphyromonas gingivalis*. *Infection and Immunity*, **1999**, 67(4), 1917-1921.
- [24] S.Sarray, V.Berthet, J.J.Calvete, J.Jeannine Secchi, J.Marvaldi, M.El Ayeb, N.Marrakchi, J. Luis, Lebectin, a novel C-type lectin from *Macrovipera lebetina* venom, inhibits integrin-mediated adhesion, migration and invasion of human tumor cells. *CLaboratory Investigation J*, **2004**, 84, 573-581.
- [25] S.A. Al-Sohaimy, E.E.Hafez, A.E.Abdelwahab, A.E. El-Saadani, Anti -HCV Lectin from Egyptian *Pisum sativum*. *Australian Basic and Applied Sciences J*, **2007**, 1(3), 213-219.
- [26] H.J.Rasha, R.H.Hathama, K.H. Majid, Detection of malignant human kidney lectins and study of their optimum hemagglutination conditions. The Proceeding of the Third Scientific Conference of College of Science, Baghdad University, **2009**, 1563-1577.